Overview
Penta Medical developed portable hardware intended to direct infrared light toward injured tissue, paired with software for recording sessions, pain, and adherence. The company participated in Y Combinator's Summer 2018 batch and described itself as smart hardware for injury recovery.[1]
Waterloo and founder materials document the concept, an early athletics feedback partner, and a professional athlete recovery case that brought attention to the product. They do not establish clinical efficacy, regulatory authorization, commercial scale, or the company's eventual outcome. No Penta-specific peer-reviewed trial, regulator record, reliable financial metric, shutdown announcement, or asset disposition was found.
Founding Story
Alexa Roeper is the clearest documented founder associated with Penta Medical. Her project archive describes the portable light-based device and companion application.[2] The complete legal founder roster and incorporation date were not established, and secondary founder lists conflict with the primary Roeper material.
Penta emerged from the University of Waterloo entrepreneurship environment and later joined YC S18. The observed sources do not establish the final product name, complete specifications, patents, or manufacturing partner.
Timeline
- Early development: Waterloo materials described photoactive fabric and wearable LED pods intended to direct or reflect infrared light toward an injured area.[3]
- Pilot context: Michigan State University Athletics was identified as an early customer and product-feedback partner.[4]
- International exposure: Waterloo News reported that work involving a professional baseball athlete recovering from a publicized fibula fracture helped introduce the product internationally.[4]
- Summer 2018: Penta Medical participated in Y Combinator.[1]
- Later status: The YC profile describes the company as inactive, but no shutdown date or legal dissolution record was found.
What They Built
The hardware concept used photoactive fabric and wearable LED pods to apply or reflect infrared light toward an injured area.[3] Roeper's archive describes a portable device paired with an application for treatment-session and soft-tissue-injury monitoring, including pain and compliance tracking.[2]
Portability and adherence records were presented as differences from clinic-based light-therapy equipment. The observed material does not establish final technical specifications, production readiness, safety testing, or a legally marketed product.
Market Position
Target Customers
Penta targeted sports-medicine teams and clinicians, where athlete availability carries competitive and financial value.[4]
Market Size
No reliable market-size, customer-count, unit-sales, pricing, or revenue evidence was found. A named athletics partner shows that development progressed beyond a bare pitch, not that procurement was repeatable.
Competition
Penta positioned portability and software tracking against clinic-based light-therapy equipment. The source packet does not provide a verified competitor set, comparative performance study, reimbursement pathway, or purchasing analysis.
Business Model
No documented pricing or revenue model was recovered. The likely commercial questions for wearable medical hardware include manufacturing, servicing, clinical sales, reimbursement, and support, but the evidence does not show how Penta planned to address them.
No reliable record establishes later funding, revenue, unit economics, manufacturing cost, customer contracts, or reimbursement. Those omissions prevent a responsible assessment of commercial viability.
Traction
The strongest documented traction is Michigan State University Athletics as an early customer and feedback partner, plus reported exposure through a professional baseball recovery case.[4] University documentation also shows that the product concept received institutional attention.
These facts do not establish therapeutic benefit, paid deployment, repeat purchases, or commercial scale. No durable operating metric was found.
Post-Mortem
There is not enough evidence for a failure mechanism. Medical hardware can face certification, quality, safety, manufacturing, liability, reimbursement, and clinical-sales burdens, but no source establishes which, if any, affected Penta.
Public descriptions used efficacy-oriented language. The bounded research found no Penta-specific peer-reviewed outcome study, registered clinical trial, FDA clearance or approval, Health Canada device licence, or confirmed classification. General photobiomodulation research cannot prove that Penta's particular device was safe, effective, or legally marketed.
The company is described as inactive, but no shutdown announcement, insolvency filing, layoff record, patent or asset transfer, application fate, or verified founder next role was found. The record cannot distinguish a quiet shutdown from a paused, renamed, unreleased, or otherwise discontinued program.
Key Lessons
- A pilot is evidence of engagement, not efficacy. A named athletics partner documents feedback activity without proving clinical outcomes.
- Product claims require product-specific evidence. General light-therapy literature cannot validate one device's safety, performance, or regulatory status.
- Missing records constrain the conclusion. Commercial and company outcomes remain unknown rather than inferable from an inactive profile.